Our Pricing

Mounjaro and Blood Clots: What the Clinical Evidence Shows

Published: 11 September 2026

Concerns about Mounjaro and blood clots are understandable given the cardiovascular risks associated with obesity, but clinical evidence suggests tirzepatide may actually reduce cardiovascular risk rather than increase it. Mounjaro (tirzepatide) is a GLP-1/GIP receptor agonist licensed in the UK for weight management, and extensive trial data has examined its effects on cardiovascular health, including thrombotic events. Understanding the real relationship between Mounjaro and blood clots requires examining both the pharmacology of tirzepatide and the outcomes from large-scale clinical trials.

Understanding Mounjaro and Blood Clots: The Clinical Evidence

The relationship between Mounjaro and blood clots has been rigorously examined in the SURPASS clinical trial programme, which enrolled over 10,000 participants across multiple studies [1]. These trials monitored cardiovascular adverse events including venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism. Importantly, the incidence of thromboembolic events in Mounjaro-treated patients was comparable to or lower than placebo groups, suggesting no increased risk attributable to tirzepatide itself.

In the SURPASS-CVOT cardiovascular outcomes trial, which specifically assessed major adverse cardiovascular events (MACE) in high-risk patients, tirzepatide demonstrated a favourable safety profile with no signal for increased thrombotic risk [2]. The trial showed that Mounjaro reduced MACE by 15% compared to placebo, indicating potential cardiovascular protective effects. This is particularly relevant for patients concerned about Mounjaro and blood clots, as the data suggests the medication may actually improve overall cardiovascular health through weight reduction and metabolic improvements.

How Mounjaro and Blood Clots Risk Compares to Obesity Itself

When evaluating Mounjaro and blood clots, it's essential to understand that obesity itself is a significant independent risk factor for venous thromboembolism. People with a BMI over 30 have approximately 2-3 times higher risk of blood clots compared to those with normal weight [3]. This elevated risk stems from chronic inflammation, endothelial dysfunction, increased coagulation factors, and reduced fibrinolysis associated with excess adiposity.

By facilitating substantial weight loss—averaging 15-22% of body weight in clinical trials—Mounjaro may actually reduce baseline thrombotic risk over time [1]. The metabolic improvements associated with tirzepatide treatment, including reduced inflammation markers, improved lipid profiles, and decreased blood pressure, all contribute to a healthier cardiovascular state. For patients weighing the risks of Mounjaro and blood clots, the evidence suggests that successful weight reduction may lower overall thrombotic risk compared to remaining at a higher weight.

Metabolic Improvements That May Reduce Clot Risk

Mounjaro's effects extend beyond weight loss to include improvements in multiple cardiovascular risk markers. Clinical trials have demonstrated reductions in systemic inflammation (measured by C-reactive protein), improvements in endothelial function, and favourable changes in coagulation parameters [2]. These metabolic shifts may collectively reduce the prothrombotic state associated with obesity and metabolic syndrome, further supporting the cardiovascular safety profile of tirzepatide.

Mounjaro and Blood Clots: Monitoring and Patient Selection

While the evidence regarding Mounjaro and blood clots is reassuring, appropriate patient selection and monitoring remain essential components of safe prescribing. At Cured Pharmacy, our UK-registered prescribers conduct comprehensive clinical assessments to identify patients with pre-existing thrombotic risk factors, including personal or family history of VTE, thrombophilia, recent surgery, or prolonged immobility. Mounjaro is available from £124.99 following clinical approval by our prescribing team.

Patients with established cardiovascular disease or multiple risk factors require individualised assessment before starting Mounjaro. The clinical consultation process evaluates your complete medical history, current medications (particularly anticoagulants or antiplatelet agents), and any contraindications. This thorough evaluation ensures that concerns about Mounjaro and blood clots are addressed through evidence-based risk stratification rather than generalised assumptions.

When Additional Monitoring May Be Recommended

Certain patient populations may warrant closer monitoring when initiating Mounjaro, particularly those with multiple cardiovascular risk factors or a history of thrombotic events. Our clinical team may recommend baseline assessment of inflammatory markers, lipid panels, and coagulation studies in selected patients. Throughout treatment, we advise patients to report any symptoms suggestive of thrombosis—including unilateral leg swelling, chest pain, or shortness of breath—though such events have not been causally linked to tirzepatide in clinical trials [4].

Comparing Mounjaro and Blood Clots Risk Across Weight Loss Treatments

When examining Mounjaro and blood clots in the context of other weight loss treatments, the cardiovascular safety data for GLP-1 receptor agonists as a class is consistently favourable. Semaglutide (Wegovy, Ozempic) demonstrated cardiovascular benefit in the SELECT trial, with a 20% reduction in major cardiovascular events [5]. This class effect suggests that incretin-based therapies may share protective cardiovascular mechanisms, including anti-inflammatory and anti-atherosclerotic properties beyond glucose and weight control.

In contrast, some historical weight loss medications have been associated with cardiovascular concerns, though none specifically with increased thrombotic risk. The modern generation of GLP-1 and dual GIP/GLP-1 agonists like Mounjaro represents a paradigm shift in weight management pharmacotherapy, with robust cardiovascular safety data supporting their use even in high-risk populations. For patients concerned about Mounjaro and blood clots, the evidence base is substantially more comprehensive and reassuring than for many alternative weight loss interventions.

Real-World Evidence on Mounjaro and Blood Clots in UK Practice

Post-marketing surveillance data from the MHRA and real-world evidence from UK clinical practice have not identified any unexpected safety signals regarding Mounjaro and blood clots since tirzepatide's approval for weight management. Pharmacovigilance systems continuously monitor adverse event reports, and thrombotic events have occurred at rates consistent with the background prevalence in the obese population rather than representing a drug-related increase [6].

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees clinical governance protocols that include systematic monitoring of patient outcomes and adverse events. Across thousands of patient consultations for weight loss treatments, the safety profile observed in real-world practice aligns with the clinical trial data showing no causal association between Mounjaro and blood clots. This concordance between controlled trial settings and everyday clinical use provides additional confidence in tirzepatide's cardiovascular safety.

Reporting and Monitoring Systems in UK Pharmacy Practice

All UK-registered pharmacies, including Cured Pharmacy (GPhC 9012511), participate in the Yellow Card scheme for reporting suspected adverse drug reactions to the MHRA. This national pharmacovigilance system ensures that any potential safety concerns, including those related to Mounjaro and blood clots, are rapidly identified and investigated. Patients can also report suspected side effects directly through the Yellow Card website, contributing to the ongoing safety monitoring of all licensed medicines.

Making an Informed Decision About Mounjaro and Blood Clots

For patients weighing the benefits and risks of Mounjaro, understanding the relationship between Mounjaro and blood clots requires considering both the direct pharmacological effects of tirzepatide and the cardiovascular benefits of substantial weight loss. The totality of evidence from randomised controlled trials, cardiovascular outcomes studies, and real-world surveillance supports a favourable safety profile with potential cardiovascular protective effects rather than increased thrombotic risk.

Your individual risk-benefit assessment should be conducted in consultation with a qualified prescriber who can evaluate your personal medical history, cardiovascular risk factors, and treatment goals. At Cured Pharmacy, our clinical team provides evidence-based guidance during the online consultation process, addressing specific concerns about Mounjaro and blood clots in the context of your unique health profile. Treatment begins only after thorough clinical assessment and prescriber approval, with ongoing support available throughout your weight loss journey. New patients can access £20 off their first order using code Weightlossnew, with transparent pricing from £124.99 displayed before consultation.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 11 September 2026]
2. Sattar, N., McGuire, D. K., Pavo, I., et al. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine, 28(3), 591-598. [accessed 11 September 2026]
3. Ageno, W., Becattini, C., Brighton, T., et al. (2008). Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation, 117(1), 93-102. [accessed 11 September 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 11 September 2026]
5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 11 September 2026]
6. Medicines and Healthcare products Regulatory Agency. (2024). Tirzepatide (Mounjaro): Drug Safety Update. MHRA Public Assessment Report. [accessed 11 September 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.